Hotel Primus “FENICE & BOLSOI” Meeting Room
Calle Menorca, 22 - 46023 Valencia

Valencia, March 7th 2015

08.00/08.05 WELCOME
WHAT IS GCA: GOALS AND EXPECTATIONS
Prof. Nicoletta Colombo, European Institute of Oncology, Milan (Italy)

08.05/10.00 TRICKS AND PITFALLS FOR A FRUITFUL NATIONAL AND INTERNATIONAL COLLABORATION:

08.05/08.15 OUTSIDE EU REGULATIONS: ACTIVATING A STUDY IN SWITZERLAND
Prof. Cristiana Sessa, Oncology Institute of Southern Switzerland - Ospedale San Giovanni, Bellinzona (Switzerland)

08.15/08.35 THE CHALLENGE OF INITIATING A NATIONAL COOPERATIVE TRIAL GROUP: TRICKS AND TIPS
Prof. Mansoor Raza Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

08.35/08.55 THE HURDLES OF CONDUCTING TRIALS ACROSS DIFFERENT COUNTRIES: FOCUS ON EU REGULATIONS AND DIFFERENCES WHICH MAY CONSTITUTE BARRIERS TO RUN AN ENGOT TRIAL
Prof. Jacobus Pfisterer, Gynecologic Oncology Center, Kiel (Germany)

08.55/09.25 HOW TO WRITE A GRANT FOR ACADEMIC TRIALS (INVESTIGATOR-INITIATED)
Prof. Sandro Pignata, National Cancer Institute Fondazione Pascale, Naples (Italy)

09.25/09.45 HOW TO NEGOTIATE SUPPORT WITH PHARMA COMPANIES FOR SPONSORED TRIALS
Prof. Andreas Du Bois, Kliniken Essen-Mitte, Essen (Germany)

09.45/10.00 Discussion

10.00/10.15 COFFEE
10.15/11.45 WORKSHOP SESSION 1 (4 TABLES): ORGANIZATION AND LAUNCH OF A SUCCESSFUL NATIONAL COOPERATIVE GROUP ACCORDING TO ENGOT STANDARD
At each table, pre-planned young trialist representatives present and discuss the strategy to set up a new cooperative trial group: define the procedure step by step

FACILITATORS: Prof. Andrés Poveda, Fundación Instituto Valenciano de Oncología, Valencia (Spain) & Prof. Mansoor Raza Mirza, Righospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
Prof. Cristiana Sessa, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona (Switzerland) & Prof. Andreas Du Bois, Klinikens Essen-Mitte, Essen (Germany)
Prof. Christian Marth, Universitätskliniken LKH, Innsbruck (Austria) & Prof. Sandro Pignata, National Cancer Institute Fondazione Pascale, Naples (Italy)
Prof. Antonio González, MD Anderson Cancer Center, Madrid (Spain)

11.45/12.30 Presentation of the results and discussion
12.30/13.30 LUNCH
13.30/14.30 IMMUNOTHERAPY IN OVARIAN CANCER
13.30/13.50 IMMUNOTHERAPY HAS NEVER WORKED AND WILL NEVER WORK IN OVARIAN CANCER
Prof. Éric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris (France)
13.50/14.10 IMMUNOTHERAPY REPRESENTS THE FUTURE FOR OVARIAN CANCER
Prof. Bradley J. Monk, St. Joseph’s Hospital and Medical Center, Phoenix AZ (USA)
14.10-14.30 Discussion
14.30/15.30 WORKSHOP SESSION 2 (4 TABLES):
DESIGN A NEW IMMUNOTHERAPY TRIAL IN OVARIAN CANCER
At each table, pre-planned young trialist representatives present and discuss the design of one future trial on immunotherapy in ovarian cancer.

FACILITATORS: Table 1: Ph1 plus translational research
Prof. Michael J. Birrer, Massachussets General Hospital, Boston MA (USA)
Table 2: Ph2 in patients in platinum resistant
Prof. Bradley J. Monk, St. Joseph’s Hospital and Medical Center, Phoenix AZ (USA)
Table 3: Ph2 in patients in platinum sensitive
Prof. Mansoor Raza Mirza, Righospitalet - Copenhagen University Hospital, Copenhagen (Denmark) & Prof. Sandro Pignata, National Cancer Institute Fondazione Pascale, Naples (Italy)
Table 4: Ph3 in front line
Prof. Christian Marth, Universitätskliniken LKH Innsbruck, Innsbruck (Austria) & Prof. Jonathan A. Ledermann, University College London Cancer Institute, London (UK)
15.30/16.00 Presentation of the results and discussion
16.00 CLOSING REMARKS

This GCA Initiative is possible thanks to generous educational grant from Roche and AstraZeneca.